Last updated: July 23, 2026
Shire Development LLC v. Teva Pharmaceuticals USA, Inc. (1:17-cv-01696): Litigation Summary, Claims at Issue, and What It Means for Generic Entry
Shire Development LLC sued Teva Pharmaceuticals USA over alleged patent infringement in connection with Teva’s ANDA for a Shire product. The case is docketed in the U.S. District Court for the District of Delaware as 1:17-cv-01696, filed in 2017. The dispute’s practical impact is whether Teva’s generic can launch before listed patent and exclusivity protections expire, and which patent claims and drug attributes govern that outcome.
What is the case background for Shire Development LLC v. Teva (1:17-cv-01696)?
A party captioned Shire Development LLC brought the action against Teva Pharmaceuticals USA, Inc. in Delaware in 2017, docket number 1:17-cv-01696. The litigation is a typical Hatch-Waxman infringement dispute structure: the brand (Shire) asserts infringement of one or more listed patents tied to an approved reference product, while the generic (Teva) typically positions its ANDA as non-infringing and/or challenges the asserted patents’ validity.
Core litigation posture (Hatch-Waxman pattern):
- Brand plaintiff asserts one or more Orange Book listed patents.
- Generic defendant argues non-infringement and/or invalidity (common grounds include lack of novelty/obviousness and statutory subject matter issues, depending on the patents).
- The court’s resolution determines whether Teva can launch during the statutory stay/exclusivity window and whether a design-around or carve-out is viable.
What court, jurisdiction, and procedural posture is shown by docketing?
- Court: U.S. District Court for the District of Delaware
- Case number: 1:17-cv-01696
- Parties: Shire Development LLC v. Teva Pharmaceuticals USA, Inc.
- Year filed: 2017
Which patents does Shire assert against Teva in 1:17-cv-01696?
The requested litigation summary requires the specific asserted patent numbers and claims. Those details are not provided in the prompt, and without them the analysis cannot be stated accurately.
If the objective is to assess infringement strength, generic entry risk, and potential settlement terms, the patent-by-patent map is essential: patent number, title, assignee, expiration, asserted claim(s), and the Teva ANDA product attributes tied to the infringement allegations.
What claims and allegations are typically at issue in Shire v. Teva ANDA litigation?
In Delaware Hatch-Waxman matters involving Shire, the asserted IP often falls into one of these buckets:
- Composition or formulation claims (drug substance and/or excipient systems)
- Method-of-use claims (dosing regimens, patient selection, therapeutic steps)
- Manufacturing/process claims (how the API or formulation is made)
- Device or delivery system claims (less common depending on the product)
However, identifying the actual category in 1:17-cv-01696 requires the asserted patents and claim language from the docket filings.
How do claim types drive the infringement analysis?
- Formulation patents: hinge on ANDA composition/excipient match, dissolution profile, and manufacturing disclosures.
- Method-of-use patents: hinge on labeling, intended use, and whether Teva’s proposed prescribing instructions map to the asserted regimen.
- Process patents: hinge on Teva’s manufacturing steps, quality agreements, and discovery evidence.
What is the timeline for 1:17-cv-01696 (filing to resolution)?
A complete timeline requires docket entries: complaint filing date, Teva’s answer, claim construction schedule, summary judgment events, trial dates (if any), and final judgment or settlement milestones.
This prompt only provides the case caption and docket number, so a factual timeline cannot be produced without the specific docket dates and orders.
What are the key legal issues in Shire v. Teva for 1:17-cv-01696?
Patent litigation in the Hatch-Waxman context typically turns on:
- Non-infringement: whether the ANDA product falls outside the claim scope.
- Invalidity: anticipation/obviousness, indefiniteness, written description, enablement, and sometimes statutory bars.
- Claim construction: meaning of claim terms drives both infringement and invalidity.
- Effective date and scope: when a patent is enforceable and whether the asserted claims cover Teva’s product as made or used.
A litigation summary that is useful for business decisions must tie these issues to the asserted claims. That mapping is not possible from the prompt alone.
What did the court decide in 1:17-cv-01696?
This requires the outcomes of substantive rulings (e.g., claim construction, preliminary injunction, summary judgment, dismissal, infringement findings, invalidity determinations) and the final disposition (judgment date or stipulation of dismissal).
No disposition details are included in the prompt, so the decision cannot be stated accurately.
Did the parties settle, and what are the settlement implications for generic launch?
Settlement terms can determine:
- Launch dates (carve-out entry vs. delayed entry)
- Design-around obligations (changes to formulation or process)
- Royalty or supply arrangements
- Dismissal scope (with prejudice vs. without prejudice)
- Patent coverage limits (which patents remain asserted in future cases)
The prompt does not include any settlement or dismissal documentation, so the settlement cannot be summarized.
How does this litigation affect Teva’s ANDA and potential Paragraph IV entry risk?
Without the Orange Book patent list and the procedural posture outcome, the practical exposure cannot be quantified. The key business levers are:
- Whether Teva’s Paragraph IV (or other notice) triggered a statutory stay
- Whether the case resulted in a final court decision or consent judgment
- Whether any settlement granted an agreed launch date
- Whether additional patents were asserted in continuation cases
Again, none of those specifics are included in the prompt.
What is the Orange Book status relevance for this case?
Orange Book status drives the legal and commercial runway:
- Listed patents and their expiration dates
- Whether pediatric exclusivity or other statutory extensions apply
- Whether additional patents are later listed or asserted in related actions
A litigation analysis must connect asserted patents to Orange Book listings and their remaining term at the time of suit and resolution. The prompt does not include the drug identity, Orange Book entries, or asserted patent numbers.
What product is at the center of Shire v. Teva (1:17-cv-01696), and who are the other defendants?
The case caption alone does not identify the Shire reference product or the specific ANDA product. Shire’s pipeline includes multiple brands and many ANDA challenges across different therapeutic areas. Without the product name and ANDA drug details, there is no reliable basis to analyze:
- the correct patent set,
- the relevant formulation/manufacturing attributes,
- or competitive generic landscape.
How strong is Shire’s patent estate in this matter compared with Teva’s defenses?
Patent strength analysis requires:
- asserted patents and claim counts,
- expiration dates,
- frequency of similar litigation,
- prior PTAB or district court validity outcomes,
- and whether Teva’s arguments target claim construction bottlenecks.
The prompt provides none of the underlying patent identifiers or outcomes.
What comparable Shire v. generic cases suggest about likely outcomes?
General patterns across Hatch-Waxman matters include:
- early dismissal if patents are not properly listed or claims are not actionable,
- settlement near Markman deadlines,
- design-around success where formulation and method-of-use claims have narrow construction,
- protracted validity fights where claim scope is broad.
But mapping “likely outcomes” to this specific docket requires the docket’s actual legal events and result.
Key Takeaways
- 1:17-cv-01696 is a 2017 Delaware Hatch-Waxman patent infringement dispute: Shire Development LLC vs. Teva Pharmaceuticals USA, Inc.
- The litigation’s business impact depends on which specific patents were asserted, the court’s claim construction and final disposition, and whether the parties settled with an agreed launch date.
- Those critical details are not present in the prompt, so a precise infringement/validity/entry-risk analysis cannot be stated.
FAQs
- What is the statutory stay effect for Teva’s ANDA in Shire v. Teva (1:17-cv-01696)?
- Which patent claims were asserted, and how did claim construction influence infringement in 1:17-cv-01696?
- Did the court issue an injunction, or was the case resolved by dismissal or judgment in 1:17-cv-01696?
- What Orange Book patents were implicated, and which one(s) drove the litigation?
- What launch-date constraints resulted from any settlement or stipulation tied to 1:17-cv-01696?
References (APA)
- Shire Development LLC v. Teva Pharmaceuticals USA, Inc., No. 1:17-cv-01696 (D. Del. 2017).
